Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) Price Target at $181.75

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $181.75.

ICUI has been the subject of several analyst reports. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Piper Sandler increased their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. KeyCorp raised their target price on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Raymond James Financial decreased their price target on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th.

Insider Transactions at ICU Medical

In related news, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the sale, the director owned 3,995 shares in the company, valued at approximately $560,977.90. This trade represents a 24.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This trade represents a 14.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its holdings in ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after acquiring an additional 690,694 shares during the period. State Street Corp lifted its position in shares of ICU Medical by 3.2% during the second quarter. State Street Corp now owns 927,799 shares of the medical instruments supplier’s stock worth $122,609,000 after purchasing an additional 28,491 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of ICU Medical by 16.9% in the third quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock valued at $104,718,000 after purchasing an additional 126,072 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after purchasing an additional 203,746 shares in the last quarter. Finally, Schroder Investment Management Group grew its holdings in shares of ICU Medical by 25.2% in the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock valued at $93,246,000 after purchasing an additional 160,380 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 2.3%

NASDAQ ICUI opened at $151.90 on Friday. ICU Medical has a 52 week low of $107.00 and a 52 week high of $175.51. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The business’s fifty day simple moving average is $126.45 and its 200-day simple moving average is $128.37. The firm has a market cap of $3.75 billion, a PE ratio of -99.93 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. During the same quarter in the prior year, the firm posted $1.59 earnings per share. ICU Medical’s quarterly revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities analysts anticipate that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.